Oncology Consultations®: Clinical Conversations Between an Oncology Nurse and Pharmacist During AML Treatment

Oncology Consultations^®: Clinical Conversations Between an Oncology Nurse and Pharmacist During AML Treatment

Faculty Presenters

Craig W. Freyer, PharmD, BCOP
Clinical Pharmacy Specialist in Hematology/Oncology,
Stem Cell Transplant, and Cellular Therapy
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Nurse Practitioner
Associate Clinical Professor
University of California San Francisco
San Francisco, California
 
Program Description
For nearly 40 years, clinicians treating patients with acute myeloid leukemia (AML) had few new treatment options. However, 2017 and 2018 were watershed years in terms of new approvals, with 8 medications approved for treatment of AML and several additional agents involved in phase 3 trials during these years. These new agents promise substantial benefits for patients with AML and offer new treatment options for health care teams. This expanding arsenal of therapies allows practitioners to hone treatment and individualize care. While novel therapies and combinations benefit patients with AML, they also add markedly to the complexity of the treatment decision-making process for a patient population with many medical comorbidities.

This Oncology Consultations® activity is a video-based program in which 2 experts use a case-based approach to discuss the treatment and management of AML. In this activity, the faculty focus on a comprehensive review of novel and emerging therapies for the management of AML in patients who are fit for intensive induction therapy and patients who are not eligible for intensive therapy, applying recent trial data to clinical practice and providing insight into the future of AML management. This engaging format is designed to help clinicians identify best practices in the management of AML and to improve outcomes for their patients with this disease.

Target Audience: This activity is directed toward oncology nurses and hematology/oncology pharmacists who manage and treat patients with acute myeloid leukemia.
Type of Activity: Application
Release date: November 6, 2020
Expiration date: November 6, 2021
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Distinguish treatment approaches for acute myeloid leukemia (AML) based on disease- and patient-specific factors
• Interpret clinical trial data of approved and emerging treatment options in AML to optimize patient care and ensure appropriate patient management
• Identify strategies for prevention and management of adverse effects associated with treatments used in AML
• Examine approaches to improve outcomes for patients with AML, emphasizing multidisciplinary care with nursing and pharmacist team members

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-9999-20-356-H01-P. The activity is available for CE credit through November 6, 2021.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Physicians and Nurses seeking credit should visit: https://www.gotoper.com/online-cme-activities/oncology-consultations/oc-aml20 to participate in this activity.

---

Disclosures

Craig W. Freyer, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Astellas Pharma, Incyte, Servier
Speakers Bureau: Astellas Pharma

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Merck

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Meg Taylor, PharmD, CPP; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms